The European Medicines Agency (EMA) has issued a recommendation for the use of an oral medicine called molnupiravir, developed by Merck, a pharmaceutical giant, against the coronavirus.
He said in a recommendation from an Amsterdam-based agency acting as the European Union’s pharmacovigilance authority that the medicine could be used in people who do not need extra oxygen during their treatment, but who are at risk of getting worse.
It is recommended that molnupiravir (also known as MK 4482 or Lagevrio) be administered as soon as possible after a positive coronavirus test or within five days of the onset of symptoms of infection. The capsule medicine should be taken twice a day for five days.
Side effects that occur within 14 days of taking the last dose of molnupiravir may include mild to moderate nausea, dizziness, diarrhea and headache. The EMA did not recommend taking the medicine during pregnancy or to use contraception during treatment for women who had an active sex life. It was added that mothers with small children should be breast-fed during treatment and for 4 days after treatment.
The EMA communication indicated that molnupiravir was still under review and was not yet authorized in the EU. Nevertheless, the EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a recommendation to help national authorities make decisions about the possible early, possible use of the medicine in an emergency.
Merck reported earlier last month that a drug called molnupiravir halved the risk of death or hospitalization in coronavirus patients. The drug company is also researching whether molnupiravir can be used to prevent the virus from spreading in households where one member is already infected. The company expects the results of related research next spring.
On 25 October, Merck applied to the European Medicines Agency for an EU authorization to introduce a new medicine for the treatment of patients with mild to moderate coronavirus disease.
Source: Propeller – Saját anyagok by propeller.hu.
*The article has been translated based on the content of Propeller – Saját anyagok by propeller.hu. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!